Alzheimer's disease (AD) remains one of the most urgent challenges in modern biomedicine. Despite substantial advances over decades in defining its pathological hallmarks, i.e., amyloid-beta (Aβ) deposition and tau pathology (1), and other key processes involved in disease pathogenesis such as neuroinflammation (2) and synaptic dysfunction (3), effective disease-modifying therapies remain limited.
Editorial: New horizons in Alzheimer's disease research: combining cell, gene, and emerging therapies
Mainardi M.
;
2026
Abstract
Alzheimer's disease (AD) remains one of the most urgent challenges in modern biomedicine. Despite substantial advances over decades in defining its pathological hallmarks, i.e., amyloid-beta (Aβ) deposition and tau pathology (1), and other key processes involved in disease pathogenesis such as neuroinflammation (2) and synaptic dysfunction (3), effective disease-modifying therapies remain limited.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
fmed-13-1919555.pdf
accesso aperto
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Creative commons
Dimensione
91.13 kB
Formato
Adobe PDF
|
91.13 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
